Skip to main content
Michael Atkin, MD, Emergency Medicine, Bronx, NY

MichaelJoshuaAtkinMD

Emergency Medicine Bronx, NY

Physician

Are you Dr. Atkin?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 30 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    600 E 233rd St
    Bronx, NY 10466
    Phone+1 718-920-9135
    Fax+1 718-920-9106

Summary

  • Dr. Michael Atkin, MD is a board certified emergency medicine physician in Bronx, New York. He is currently licensed to practice medicine in New York and New Jersey. He is affiliated with Montefiore Medical Center - Wakefield Campus and Hackensack Meridian Health Raritan Bay and Old Bridge Medical Centers.

Education & Training

  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellResidency, Emergency Medicine, 2005 - 2008
  • Westchester Medical Center
    Westchester Medical CenterInternship, Internal Medicine, 2004 - 2005
  • Tel Aviv University Sackler
    Tel Aviv University SacklerClass of 2004

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2012 - 2025
  • NY State Medical License
    NY State Medical License 2008 - 2023
  • American Board of Emergency Medicine Emergency Medicine

Press Mentions

  • Ortho Regenerative Technologies Reports Its Fourth Quarter and 2021 Year-End Results
    Ortho Regenerative Technologies Reports Its Fourth Quarter and 2021 Year-End ResultsJune 1st, 2021
  • How AR Is Transforming Spine Surgery & More: 7 Device Company Notes
    How AR Is Transforming Spine Surgery & More: 7 Device Company NotesJune 24th, 2020
  • Ortho RTI Appoints Board Chair as Company Nears 1st Clinical Trial
    Ortho RTI Appoints Board Chair as Company Nears 1st Clinical TrialJune 22nd, 2020